Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IHE iShares U.S. Pharmaceuticals ETF	$71.32 +0.1%	$68.34	$58.97 ▼ $73.28	$584.82M	0.7	75,526 shs	28,615 shs
JNJ Johnson & Johnson	$178.20 -0.3%	$168.57	$140.68 ▼ $181.16	$429.72B	0.4	7.56 million shs	9.73 million shs
MRK Merck & Co., Inc.	$84.59 +0.6%	$82.62	$73.31 ▼ $120.30	$211.59B	0.37	10.42 million shs	13.23 million shs
NVS Novartis	$129.76 +1.0%	$121.25	$96.06 ▼ $130.46	$274.04B	0.63	1.12 million shs	1.34 million shs
PFE Pfizer	$24.86 +1.3%	$24.85	$20.92 ▼ $30.43	$141.46B	0.55	34.76 million shs	34.59 million shs
PJP Invesco Pharmaceuticals ETF	$92.87 +0.6%	$85.81	$72.25 ▼ $92.99	$266.53M	0.66	7,260 shs	5,560 shs
XPH SPDR S&P Pharmaceuticals ETF	$47.85 +1.2%	$43.89	$35.22 ▼ $48.76	$172.26M	0.84	48,543 shs	42,541 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IHE iShares U.S. Pharmaceuticals ETF	0.00%	+0.22%	+8.49%	+7.59%	-1.53%
JNJ Johnson & Johnson	0.00%	+0.62%	+3.96%	+14.95%	+6.53%
MRK Merck & Co., Inc.	0.00%	+0.54%	+5.35%	+7.14%	-26.95%
NVS Novartis	0.00%	+2.65%	+11.97%	+9.95%	+8.70%
PFE Pfizer	0.00%	+0.47%	+2.52%	+6.40%	-12.42%
PJP Invesco Pharmaceuticals ETF	0.00%	+1.93%	+10.64%	+13.85%	+5.56%
XPH SPDR S&P Pharmaceuticals ETF	0.00%	+0.80%	+12.48%	+14.09%	+8.06%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IHE iShares U.S. Pharmaceuticals ETF	$71.32 +0.1%	$68.34	$58.97 ▼ $73.28	$584.82M	0.7	75,526 shs	28,615 shs
JNJ Johnson & Johnson	$178.20 -0.3%	$168.57	$140.68 ▼ $181.16	$429.72B	0.4	7.56 million shs	9.73 million shs
MRK Merck & Co., Inc.	$84.59 +0.6%	$82.62	$73.31 ▼ $120.30	$211.59B	0.37	10.42 million shs	13.23 million shs
NVS Novartis	$129.76 +1.0%	$121.25	$96.06 ▼ $130.46	$274.04B	0.63	1.12 million shs	1.34 million shs
PFE Pfizer	$24.86 +1.3%	$24.85	$20.92 ▼ $30.43	$141.46B	0.55	34.76 million shs	34.59 million shs
PJP Invesco Pharmaceuticals ETF	$92.87 +0.6%	$85.81	$72.25 ▼ $92.99	$266.53M	0.66	7,260 shs	5,560 shs
XPH SPDR S&P Pharmaceuticals ETF	$47.85 +1.2%	$43.89	$35.22 ▼ $48.76	$172.26M	0.84	48,543 shs	42,541 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IHE iShares U.S. Pharmaceuticals ETF	0.00%	+0.22%	+8.49%	+7.59%	-1.53%
JNJ Johnson & Johnson	0.00%	+0.62%	+3.96%	+14.95%	+6.53%
MRK Merck & Co., Inc.	0.00%	+0.54%	+5.35%	+7.14%	-26.95%
NVS Novartis	0.00%	+2.65%	+11.97%	+9.95%	+8.70%
PFE Pfizer	0.00%	+0.47%	+2.52%	+6.40%	-12.42%
PJP Invesco Pharmaceuticals ETF	0.00%	+1.93%	+10.64%	+13.85%	+5.56%
XPH SPDR S&P Pharmaceuticals ETF	0.00%	+0.80%	+12.48%	+14.09%	+8.06%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IHE iShares U.S. Pharmaceuticals ETF	2.65	Moderate Buy	$71.32	N/A
JNJ Johnson & Johnson	2.65	Moderate Buy	$176.29	-1.07% Downside
MRK Merck & Co., Inc.	2.35	Hold	$107.44	27.01% Upside
NVS Novartis	2.11	Hold	$124.33	-4.18% Downside
PFE Pfizer	2.39	Hold	$28.12	13.13% Upside
PJP Invesco Pharmaceuticals ETF	2.73	Moderate Buy	$92.87	N/A
XPH SPDR S&P Pharmaceuticals ETF	2.70	Moderate Buy	$47.85	N/A

Current Analyst Ratings Breakdown

Latest PFE, MRK, JNJ, NVS, PJP, IHE, and XPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	NVS Novartis	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/21/2025	JNJ Johnson & Johnson	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$185.00 ➝ $200.00
8/8/2025	NVS Novartis	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$123.00
8/6/2025	PFE Pfizer	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$25.00 ➝ $26.00
8/6/2025	PFE Pfizer	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$32.00 ➝ $33.00
8/6/2025	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$27.00 ➝ $28.00
7/30/2025	MRK Merck & Co., Inc.	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$97.00 ➝ $90.00
7/23/2025	JNJ Johnson & Johnson	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
7/17/2025	JNJ Johnson & Johnson	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/17/2025	JNJ Johnson & Johnson	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$165.00 ➝ $176.00
7/17/2025	JNJ Johnson & Johnson	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$181.00 ➝ $185.00

(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IHE iShares U.S. Pharmaceuticals ETF	N/A	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$88.82B	4.83	$13.10 per share	13.60	$29.69 per share	6.00
MRK Merck & Co., Inc.	$64.17B	3.29	$9.45 per share	8.95	$18.33 per share	4.61
NVS Novartis	$50.32B	5.45	$10.71 per share	12.12	$21.59 per share	6.01
PFE Pfizer	$63.63B	2.22	$4.36 per share	5.70	$15.62 per share	1.59
PJP Invesco Pharmaceuticals ETF	N/A	N/A	N/A	N/A	N/A	N/A
XPH SPDR S&P Pharmaceuticals ETF	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IHE iShares U.S. Pharmaceuticals ETF	N/A	N/A	17.75	∞	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$14.07B	$9.35	19.06	16.10	2.27	25.00%	32.49%	13.00%	10/14/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.49	13.03	8.54	0.89	25.79%	41.05%	16.55%	10/30/2025 (Estimated)
NVS Novartis	$11.94B	$6.87	18.89	14.73	1.82	25.64%	41.08%	16.83%	11/4/2025 (Estimated)
PFE Pfizer	$8.03B	$1.88	13.22	8.20	0.88	16.84%	21.42%	9.12%	11/4/2025 (Estimated)
PJP Invesco Pharmaceuticals ETF	N/A	N/A	15.59	∞	N/A	N/A	N/A	N/A	N/A
XPH SPDR S&P Pharmaceuticals ETF	N/A	N/A	14.28	∞	N/A	N/A	N/A	N/A	N/A

Latest PFE, MRK, JNJ, NVS, PJP, IHE, and XPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	$2.13	+$0.10	$1.76	$15.92 billion	$15.81 billion
7/17/2025	Q2 2025	NVS Novartis	$2.38	$2.42	+$0.04	$2.06	$13.94 billion	$14.05 billion
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.68	$2.77	+$0.09	$2.29	$22.85 billion	$23.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IHE iShares U.S. Pharmaceuticals ETF	$1.16	1.63%	N/A	N/A	N/A
JNJ Johnson & Johnson	$5.20	2.92%	N/A	55.61%	64 Years
MRK Merck & Co., Inc.	$3.24	3.83%	N/A	49.92%	14 Years
NVS Novartis	$2.60	2.00%	N/A	37.85%	N/A
PFE Pfizer	$1.72	6.92%	N/A	91.49%	16 Years
PJP Invesco Pharmaceuticals ETF	$0.96	1.03%	N/A	N/A	N/A
XPH SPDR S&P Pharmaceuticals ETF	$0.59	1.23%	N/A	N/A	N/A

Latest PFE, MRK, JNJ, NVS, PJP, IHE, and XPH Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/22/2025	MRK Merck & Co., Inc.	quarterly	$0.81	3.97%	9/15/2025	9/15/2025	10/7/2025
7/16/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.35%	8/26/2025	8/26/2025	9/9/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IHE iShares U.S. Pharmaceuticals ETF	N/A	N/A	N/A
JNJ Johnson & Johnson	0.50	1.01	0.76
MRK Merck & Co., Inc.	0.69	1.42	1.17
NVS Novartis	0.53	0.82	0.62
PFE Pfizer	0.65	1.16	0.85
PJP Invesco Pharmaceuticals ETF	N/A	N/A	N/A
XPH SPDR S&P Pharmaceuticals ETF	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IHE iShares U.S. Pharmaceuticals ETF	N/A
JNJ Johnson & Johnson	69.55%
MRK Merck & Co., Inc.	76.07%
NVS Novartis	13.12%
PFE Pfizer	68.36%
PJP Invesco Pharmaceuticals ETF	N/A
XPH SPDR S&P Pharmaceuticals ETF	N/A

Insider Ownership

Company	Insider Ownership
IHE iShares U.S. Pharmaceuticals ETF	N/A
JNJ Johnson & Johnson	0.16%
MRK Merck & Co., Inc.	0.13%
NVS Novartis	0.01%
PFE Pfizer	0.06%
PJP Invesco Pharmaceuticals ETF	N/A
XPH SPDR S&P Pharmaceuticals ETF	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IHE iShares U.S. Pharmaceuticals ETF	N/A	8.20 million	N/A	Not Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.50 billion	2.49 billion	Optionable
NVS Novartis	75,883	2.11 billion	2.11 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
PJP Invesco Pharmaceuticals ETF	N/A	2.87 million	N/A	Not Optionable
XPH SPDR S&P Pharmaceuticals ETF	N/A	3.60 million	N/A	Not Optionable

PFE, MRK, JNJ, NVS, PJP, IHE, and XPH Headlines

Recent News About These Companies

Short bets on S&P 500 Healthcare sector ease in July; Moderna remains most heavily shorted stock

August 15, 2025 | msn.com

5 Biggest Pharmaceutical ETFs in 2025

August 14, 2025 | msn.com

XPH: Healthcare Dashboard For July

July 15, 2025 | seekingalpha.com

SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.0959

June 23, 2025 | msn.com

Short bets against S&P 500 healthcare stocks climb in April; MRNA retains top shorted ranking

May 15, 2025 | msn.com

ETFs on the Move Post U.S.-China Trade Deal

May 12, 2025 | zacks.com

A Look at Pharma ETFs After Strong Q1 Earnings

May 8, 2025 | zacks.com

Capture European Growth with This Banking-Focused ETF

April 22, 2025 | theglobeandmail.com

SPDR S&P Biotech ETF declares quarterly distribution of $0.0053

March 24, 2025 | msn.com

SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.1548

December 23, 2024 | msn.com

SPDR® S&P Regional Banking ETF

December 20, 2024 | morningstar.comM

1 No-Brainer Small-Cap S&P Index Fund to Buy Right Now for Less Than $200

November 21, 2024 | msn.com

Shuttle Pharmaceuticals prices $4.5M at-the-market offering at $1.525 per share

October 30, 2024 | markets.businessinsider.com

Balanced Outlook on Apellis Pharmaceuticals: Promising Empaveli Data Amid Syfovre Growth Challenges

October 28, 2024 | markets.businessinsider.com

Bristol Myers Squibb: A High-Yield Bargain With Growth On The Horizon

October 6, 2024 | seekingalpha.com

Bottom-up default shifts significantly lower for telecoms, pharma; higher for tech

August 30, 2024 | msn.com

Pharma ETFs in Focus Post Solid Q2 Earnings

August 14, 2024 | zacks.com

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

July 24, 2024 | zacks.com

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

July 17, 2024 | zacks.com

Finding Opportunity in Unloved Healthcare ETFs

May 31, 2024 | etftrends.comE

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PFE, MRK, JNJ, NVS, PJP, IHE, and XPH Company Descriptions

iShares U.S. Pharmaceuticals ETF NYSEARCA:IHE

$71.32 +0.08 (+0.11%)

Closing price 09/5/2025 04:10 PM Eastern

Extended Trading

$71.34 +0.02 (+0.03%)

As of 09/5/2025 06:39 PM Eastern

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund's investment advisor is BlackRock Fund Advisors.

Johnson & Johnson NYSE:JNJ

$178.20 -0.57 (-0.32%)

Closing price 09/5/2025 03:59 PM Eastern

Extended Trading

$178.50 +0.31 (+0.17%)

As of 09/5/2025 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Merck & Co., Inc. NYSE:MRK

$84.59 +0.54 (+0.64%)

Closing price 09/5/2025 03:59 PM Eastern

Extended Trading

$84.77 +0.18 (+0.22%)

As of 09/5/2025 07:59 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novartis NYSE:NVS

$129.76 +1.34 (+1.04%)

Closing price 09/5/2025 03:59 PM Eastern

Extended Trading

$131.46 +1.71 (+1.32%)

As of 09/5/2025 07:22 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Pfizer NYSE:PFE

$24.86 +0.32 (+1.28%)

Closing price 09/5/2025 03:59 PM Eastern

Extended Trading

$24.85 0.00 (-0.02%)

As of 09/5/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Invesco Pharmaceuticals ETF NYSEARCA:PJP

$92.87 +0.57 (+0.62%)

Closing price 09/5/2025 04:10 PM Eastern

Extended Trading

$92.86 -0.02 (-0.02%)

As of 09/5/2025 04:10 PM Eastern

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. The Index consists of stocks of 30 United States pharmaceutical companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The Fund normally invests at least 90% of its total assets in common stocks that consists of the Index. The Fund's investment advisor is Invesco PowerShares Capital Management LLC.

SPDR S&P Pharmaceuticals ETF NYSEARCA:XPH

$47.85 +0.57 (+1.21%)

Closing price 09/5/2025 04:10 PM Eastern

Extended Trading

$47.82 -0.03 (-0.06%)

As of 09/5/2025 06:52 PM Eastern

SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Pharmaceuticals Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PFE, MRK, JNJ, NVS, PJP, IHE, and XPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PFE, MRK, JNJ, NVS, PJP, IHE, and XPH Earnings

Compare Dividends

Latest PFE, MRK, JNJ, NVS, PJP, IHE, and XPH Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PFE, MRK, JNJ, NVS, PJP, IHE, and XPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PFE, MRK, JNJ, NVS, PJP, IHE, and XPH Company Descriptions

iShares U.S. Pharmaceuticals ETF NYSEARCA:IHE

Johnson & Johnson NYSE:JNJ

Merck & Co., Inc. NYSE:MRK

Novartis NYSE:NVS

Pfizer NYSE:PFE

Invesco Pharmaceuticals ETF NYSEARCA:PJP

SPDR S&P Pharmaceuticals ETF NYSEARCA:XPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools